Sarepta Therapeutics Inc (SRPT)

Debt-to-capital ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	1,132,520	1,544,290	1,096,880	992,493	681,900
Total stockholders’ equity	US$ in thousands	859,337	384,950	928,009	761,759	818,187
Debt-to-capital ratio		0.57	0.80	0.54	0.57	0.45

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,132,520K ÷ ($1,132,520K + $859,337K)
= 0.57

The debt-to-capital ratio of Sarepta Therapeutics Inc has exhibited some fluctuation over the past five years. In 2023, the ratio stands at 0.57, indicating that 57% of the company's capital structure is funded by debt. This represents a decrease from the previous year's ratio of 0.80 but remains higher than the ratios recorded in 2021 and 2019. The 2023 ratio suggests that Sarepta Therapeutics Inc relies moderately on debt to finance its operations and investments, although the decrease from the prior year may suggest a positive trend towards potentially less reliance on debt financing. Overall, further analysis and consideration of the company's overall financial health and industry benchmarks would be necessary to fully assess the implications of this debt-to-capital ratio trend.